ZoomMed inc.

ZoomMed inc.

December 02, 2005 23:59 ET

Zoommed: Common Share offering eligible for inclusion in an SME Growth Stock Plan

MONTREAL, Dec. 2 - ZoomMed Inc. ("ZoomMed"), TSX Venture:
ZMD. M. Yves Marmet, President and Chief Executive Officer, announced on
November 24, 2005 that the corporation has filed a preliminary prospectus on
November 8, 2005 with "les Autorités des Marchés Financiers" in Quebec and

A minimum of 3,750,000 Common Shares of the Corporation and a maximum of
12,500,000 Common Shares of the Corporation are being offered under this
prospectus at a price of $0.20 per Common Share for minimum gross proceeds of
$750,000 and maximum gross proceeds of $2,500,000.

Furthermore, ZoomMed has obtained, on November 22, 2005, an advance
income tax ruling from the "Ministère du Revenu du Québec" in order to confirm
that the Common Shares of ZoomMed to be issued pursuant to this Offering will
be eligible shares, upon issuance, for inclusion in an SME Growth Stock Plan
in accordance with the announcements contained in the Additional Information
on the Budgetary Measures of the 2005-2006 Budget tabled on April 21, 2005 and
the current provisions of the Taxation Act (Québec), subject to certain
conditions contained thereunder.

ZoomMed is presently developing a new electronic tool "ZRx Prescriber",
intended to change the way drugs are prescribed and dispensed throughout
Canada. This handheld prescribing system device, equipped with tools such as a
therapeutic advisor as well as a medication interaction manager, will enable
doctors to fill prescriptions and to electronically transmit them in a fast
and secure mode. This user friendly Web product, designed for doctors, will
use the latest "Pocket PC" technologies.

ZoomMed Inc. files its financial statements, press releases and other
required filing documents on the SEDAR data base at www.sedar.com.

The preliminary prospectus is subject to approval by "les Autorités des
Marchés financiers".

The TSX Venture Exchange has neither approved nor accepts any
responsibility with respect to the veracity or exactitude of this press

Contact Information